Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

New oral anticoagulants for patients with nonvalvular atrial fibrillation

New oral anticoagulants for patients with nonvalvular atrial fibrillation CME New oral anticoagulants for patients with nonvalvular atrial fi brillation Amber Holden, PA-C; Nassir Azimi, MD, FACC, FSCAI; Christopher P. Forest, MSHS, DFAAPA, PA-C ABSTRACT Four new oral anticoagulants have been approved for reduc- ing stroke risk in patients with nonvalvular atrial fi brilla- tion. Compared with warfarin, these agents offer a more predictable dose response with fewer food and drug interac- tions and no regular blood monitoring, although some of the drugs have an increased risk of major gastrointestinal bleeding. This article reviews the new drugs. Keywords: anticoagulation, nonvalvular atrial fi brillation, rivaroxaban, dabigatran, edoxaban, apixaban Learning objectives Discuss patients’ elevated stroke risk due to AF and the role of warfarin as the established therapy for stroke prevention. Describe the mechanisms, outcomes, and roles in stroke pre- vention for recently approved non-warfarin anticoagulants. FIGURE 1. Light micrograph of a section through an arterial Describe complications and warnings for using anticoagu- thrombus lants for stroke prevention in patients with AF. and decreased overall cost to the healthcare system. Before selecting a new agent, providers must understand ith the advent of new oral anticoagulants that the nature of AF and the rationale for each of these do not require http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the American Academy of Physician Assistants Wolters Kluwer Health

New oral anticoagulants for patients with nonvalvular atrial fibrillation

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/new-oral-anticoagulants-for-patients-with-nonvalvular-atrial-lD3lAkEYQh

References (24)

Publisher
Wolters Kluwer Health
ISSN
1547-1896
eISSN
0893-7400
DOI
10.1097/01.JAA.0000471615.92278.1c
Publisher site
See Article on Publisher Site

Abstract

CME New oral anticoagulants for patients with nonvalvular atrial fi brillation Amber Holden, PA-C; Nassir Azimi, MD, FACC, FSCAI; Christopher P. Forest, MSHS, DFAAPA, PA-C ABSTRACT Four new oral anticoagulants have been approved for reduc- ing stroke risk in patients with nonvalvular atrial fi brilla- tion. Compared with warfarin, these agents offer a more predictable dose response with fewer food and drug interac- tions and no regular blood monitoring, although some of the drugs have an increased risk of major gastrointestinal bleeding. This article reviews the new drugs. Keywords: anticoagulation, nonvalvular atrial fi brillation, rivaroxaban, dabigatran, edoxaban, apixaban Learning objectives Discuss patients’ elevated stroke risk due to AF and the role of warfarin as the established therapy for stroke prevention. Describe the mechanisms, outcomes, and roles in stroke pre- vention for recently approved non-warfarin anticoagulants. FIGURE 1. Light micrograph of a section through an arterial Describe complications and warnings for using anticoagu- thrombus lants for stroke prevention in patients with AF. and decreased overall cost to the healthcare system. Before selecting a new agent, providers must understand ith the advent of new oral anticoagulants that the nature of AF and the rationale for each of these do not require

Journal

Journal of the American Academy of Physician Assistants – Wolters Kluwer Health

Published: Nov 1, 2015

There are no references for this article.